Boehringer in research collaboration with Domain Therapeutics
04-12-2018
filograph / iStockphoto.com
Boehringer Ingelheim has teamed up with academic institutions and research companies in the UK to develop a long-term gene therapy for cystic fibrosis, according to a statement released on Monday, August 6.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Boehringer, Imperial Innovations, Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, gene therapy, research and development, commercialisation